Send to printer »

GEN News Highlights : Feb 2, 2007

CSL Behring and Bayer Extend Agreement Related to Hemophilia

Global distribution of Helixate recombinant coagulation Factor VIII will run through 2017.

CSL Behring reached an agreement with Bayer HealthCare to continue the supply and distribution of a therapy for the treatment of hemophilia A. Bayer will provide Helixate® recombinant coagulation Factor VIII to CSL Behring through 2017.

Additionally, Bayer was granted a license to intellectual property related to recombinant FVIII. At the same time, the companies settled outstanding litigation relating to the supply of recombinant Factor VIII.